Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10131983 | 0.84 | MAPT (0.52) | SMN1; SMN2RAB9ANPC1HPGDTP53 | |
| SCHEMBL7882626 | 0.81 | MAPT (0.46) | SMN1; SMN2RAB9ANPC1MAPTKMT2A | |
| SCHEMBL16352669 | 0.81 | ALDH1A1 (0.40) | SMN1; SMN2RAB9ANPC1ALDH1A1KMT2A | |
| SCHEMBL75589 | 0.80 | KMT2A (0.43) | SMN1; SMN2RAB9APOLBMAPTALDH1A1 | |
| SCHEMBL15709787 | 0.80 | ALDH1A1 (0.44) | SMN1; SMN2RAB9AHPGDMAPTALDH1A1 | |
| SCHEMBL23886621 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2RAB9ANPC1MAPTALDH1A1 | |
| SCHEMBL534151 | 0.80 | MAPT (0.48) | SMN1; SMN2RAB9ANPC1POLBTP53 | |
| SCHEMBL4126633 | 0.80 | P2RX7 (0.45) | SMN1; SMN2RAB9ANPC1POLBMAPT | |
| SCHEMBL3611719 | 0.79 | AKR1B1 (0.52) | SMN1; SMN2MAPTALDH1A1KMT2AHTT | |
| SCHEMBL30546480 | 0.79 | AKR1B1 (0.52) | SMN1; SMN2MAPTALDH1A1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-11352343-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20200299272-A1 | Urea Derivatives and Uses Thereof | KALA BIO, Inc. | 2020-09-24 | — | — | US | disclosed |
| US-10723719-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190284172-A1 | Urea Derivatives and Uses Thereof | KALA BIO, Inc. | 2019-09-19 | — | — | US | disclosed |
| US-10329280-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-10316022-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180037573-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2018-02-08 | — | — | US | disclosed |
| US-20180037572-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2018-02-08 | — | — | US | disclosed |
| US-20180037572-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2018-02-08 | — | — | US | disclosed |
| US-20160060264-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2016-03-03 | — | — | US | disclosed |
| US-20160060264-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2016-03-03 | — | — | US | disclosed |
| US-9212145-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-9212145-B2 | Urea derivatives and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150072986-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2015-03-12 | — | — | US | disclosed |
| US-20150072986-A1 | UREA DERIVATIVES AND USES THEREOF | KALA BIO, Inc. | 2015-03-12 | — | — | US | disclosed |
| WO-2014201127-A2 | UREA DERIVATIVES AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2010-11-11 | — | — | US | disclosed |
| WO-2008148853-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GLAXO GROUP LIMITED (GB) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072986-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | SMN1; SMN2 4796/4885RAB9A 277/4885NPC1 3661/4885 |
| US-10316022-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | SMN1; SMN2 4796/4885RAB9A 277/4885NPC1 3661/4885 |
| US-11352343-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | SMN1; SMN2 4796/4885RAB9A 277/4885NPC1 3661/4885 |
| US-20180037572-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | SMN1; SMN2 4796/4885RAB9A 277/4885NPC1 3661/4885 |
| US-10723719-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | SMN1; SMN2 4796/4885RAB9A 277/4885NPC1 3661/4885 |
| US-20180037573-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | SMN1; SMN2 4796/4885RAB9A 277/4885NPC1 3661/4885 |
| US-20200299272-A1 | Urea Derivatives and Uses Thereof | UACA, RB1, FLT1 | SMN1; SMN2 4796/4885RAB9A 277/4885NPC1 3661/4885 |
| US-10329280-B2 | Urea derivatives and uses thereof | UACA, RB1, FLT1 | SMN1; SMN2 4796/4885RAB9A 277/4885NPC1 3661/4885 |
| US-20190284172-A1 | Urea Derivatives and Uses Thereof | UACA, RB1, FLT1 | SMN1; SMN2 4796/4885RAB9A 277/4885NPC1 3661/4885 |
| US-20100286152-A1 | N-PHENYL HYDRAZIDES AS MODULATORS OF THE GHRELIN RECEPTOR | GIPR, GHSR, GLP1R | SMN1; SMN2 3692/4885RAB9A 1127/4885NPC1 975/4885 |
| US-20160060264-A1 | UREA DERIVATIVES AND USES THEREOF | UACA, RB1, FLT1 | SMN1; SMN2 4796/4885RAB9A 277/4885NPC1 3661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.